---

Part A: Vision - Complete Guide (Chapters 142-148)

---

Chapter 142 - Functional Anatomy of the Eye

Coats of the Eye

• Sclera: tough outer protective coat; continuous anteriorly with the cornea
• Cornea: transparent avascular tissue; provides ~40 diopters (2/3) of total refractive power
• Choroid: vascular, pigmented middle coat providing nutrition to outer retinal layers
• Retina: innermost coat; contains photoreceptors (rods and cones)

Refractive Media (in order)

• Total refractive power of the eye = 59 diopters (accommodated for distance)
• Cornea contributes ~40 D; Lens contributes ~20 D in resting state

Lens and Accommodation

• For near vision: Ciliary muscle contracts (both meridional and circular fibers) → ligaments relax → lens becomes more spherical (more convex) → greater refractive power (up to 34 D in children)
• For distant vision: Ciliary muscle relaxes → ligaments taut → lens flattened
• Range of accommodation in children: up to 14 diopters; progressively lost with age (presbyopia)

Retinal Layers (inside to out)

1. Internal limiting membrane
2. Nerve fiber layer (ganglion cell axons)
3. Ganglion cell layer - only output neurons of the retina
4. Inner plexiform layer
5. Inner nuclear layer (bipolar, horizontal, amacrine cells)
6. Outer plexiform layer
7. Outer nuclear layer (rod and cone nuclei)
8. Photoreceptor layer (outer segments of rods and cones)
9. Retinal pigment epithelium (RPE)

Fovea and Macula

• Fovea centralis: ~0.5 mm diameter; contains only cones (no rods, no overlying cells)
• This is the point of maximum visual acuity
• The optic disc (blind spot) contains no photoreceptors; located ~15° nasal to the fovea

Clinical Correlations - Anatomy

Drugs for Refractive Errors / Lens Disorders

• Cataract surgery (IOL): No pharmacological correction; post-op topical antibiotics (moxifloxacin), NSAIDs (ketorolac), steroids (prednisolone acetate)
• Cycloplegics (for refraction testing): Atropine, cyclopentolate, tropicamide (block muscarinic receptors → ciliary muscle paralysis)
• Mydriatics (pupil dilation): Phenylephrine (alpha-1 agonist), tropicamide

---

Chapter 143 - Image-Forming Mechanism

Optics of the Eye

• Light refracted at anterior corneal surface (main site) and at lens surfaces
• The "reduced eye" model: single refractive surface 17 mm in front of retina, 59 D total power
• Image formed on retina is inverted and reversed - the brain learns to interpret this as upright

Pupillary Light Reflex (regulates image quality)

• Smaller pupil → greater depth of focus, sharper image, but less light
• Pathway: Light → Retina → Optic nerve → Pretectal nucleus (midbrain) → Edinger-Westphal nucleus → Ciliary ganglion → Sphincter pupillae (constriction via muscarinic M3 receptors)

Accommodation Reflex (near triad)

1. Lens becomes more convex (ciliary muscle contraction)
2. Pupil constricts (increases depth of focus)
3. Eyes converge (medial recti contract) All three driven by parasympathetic (Edinger-Westphal nucleus) and the frontal eye fields

Clinical Correlations - Image Formation

Drugs Acting on Pupil

---

Chapter 144 - Photoreceptor Mechanism

Rods vs Cones

Phototransduction Cascade (Rods)

• High cGMP → cGMP-gated Na⁺ channels open → Na⁺ influx (dark current) → depolarized state → continuous glutamate release

1. 11-cis retinal → all-trans retinal (structural change in rhodopsin)
2. Rhodopsin activates Transducin (G protein)
3. Transducin activates phosphodiesterase (PDE)
4. PDE breaks down cGMP → decreased cGMP
5. cGMP-gated Na⁺ channels close
6. Cell hyperpolarizes (unique - opposite of other sensory receptors)
7. Glutamate release decreases
8. Signal transmitted to bipolar cells → ganglion cells → optic nerve

Rhodopsin Regeneration

• Rhodopsin = scotopsin + 11-cis retinal (derived from Vitamin A)
• After bleaching: all-trans retinal → (retinal isomerase) → 11-cis retinal → recombines with scotopsin
• Alternative: all-trans retinal → all-trans retinol (Vitamin A) → 11-cis retinol → 11-cis retinal

Retinal Cell Responses to Light

• Rods, Cones, Horizontal cells: Hyperpolarize (graded potentials)
• Bipolar cells: Either hyperpolarize or depolarize (graded)
• Amacrine cells: Depolarize, generate spikes
• Ganglion cells: Only cells generating action potentials (propagated spikes)

Clinical Correlations - Photoreceptors

Key Drugs

• Vitamin A (retinol): Essential for rhodopsin synthesis; deficiency → night blindness → xerophthalmia → blindness
• Sildenafil (Viagra): Inhibits retinal PDE (same enzyme as penile PDE-5) → transient blue-green color weakness (side effect)
• Anti-VEGF agents (wet AMD): Ranibizumab (Lucentis), Bevacizumab (Avastin, off-label), Aflibercept (Eylea), Brolucizumab, Faricimab - intravitreal injection
• AREDS2 formula (dry AMD): Vitamin C, Vitamin E, Lutein, Zeaxanthin, Zinc, Copper
• Luxturna (voretigene neparvovec): First FDA-approved gene therapy for inherited retinal dystrophy due to RPE65 mutations

---

Chapter 145 - Visual Pathway and Visual Cortex

Complete Visual Pathway

Retina (photoreceptors → bipolar cells → ganglion cells)
    ↓
Optic nerve (CN II)
    ↓
Optic chiasm [nasal fibers CROSS; temporal fibers stay ipsilateral]
    ↓
Optic tract
    ↓
Lateral Geniculate Nucleus (LGN) of Thalamus
    ↓
Optic radiation (Geniculocalcarine tract)
    ↓
Primary Visual Cortex (V1) - calcarine fissure, occipital lobe (Area 17)

Key Anatomical Details

• Nasal retinal fibers (serving temporal visual fields) decussate
• Temporal retinal fibers (serving nasal visual fields) remain ipsilateral
• Therefore: Right optic tract = left half of both retinas = left visual field

• Layers I, IV, VI: crossed fibers (contralateral nasal retina)
• Layers II, III, V: uncrossed fibers (ipsilateral temporal retina)
• Signals from the two eyes remain segregated in LGN
• Magnocellular layers (1-2): movement, depth, flicker (M pathway)
• Parvocellular layers (3-6): color, texture, fine detail, shape (P pathway)

• Upper fibers (from lower visual field) → superior lip of calcarine fissure
• Lower fibers (Meyer's loop, temporal lobe) → inferior lip of calcarine fissure
• Macular representation is largest and most posterior

• V1 (Area 17, striate cortex): Primary visual cortex in calcarine fissure
• V2 (Area 18): Secondary visual processing
• V4: Color processing
• V5/MT: Motion processing
• Dorsal pathway (parietal, "where"): Motion, spatial processing
• Ventral pathway (temporal, "what"): Object recognition, faces, color

1. Suprachiasmatic nucleus (hypothalamus) - circadian rhythm entrainment
2. Pretectal nuclei (midbrain) - pupillary light reflex, focus
3. Superior colliculus - rapid saccadic eye movements
4. Ventral thalamus/basal regions - behavioral responses

Visual Field Defects - Clinical Correlation (MOST IMPORTANT)

Drugs/Treatment for Visual Pathway Disorders

• IV Methylprednisolone 1g/day x 3 days (hastens recovery, doesn't change final outcome)
• Then oral prednisone taper
• For NMOSD (NMO spectrum disorder): Eculizumab, Inebilizumab, Satralizumab, Ravulizumab (FDA-approved)
• Long-term immunosuppression: Azathioprine, Mycophenolate mofetil, Rituximab

• NAION (non-arteritic): Aspirin; risk factor control
• AAION (arteritic, GCA): High-dose oral prednisone immediately (60-80 mg/day); may need IV methylprednisolone

---

Chapter 146 - Visual Acuity, Visual Field, Light & Dark Adaptation, and Visual Reflexes

Visual Acuity

• Defined as the minimum angle of separation between two point sources that can be distinguished
• Normal: 25 seconds of arc (minimum resolvable angle); 20/20 Snellen chart at 20 feet
• Determined by cone density in the fovea (cone diameter ~1.5 µm; minimum spacing ~2 µm)
• 20/200 vision = "legal blindness" in the USA

Visual Field Testing

• Confrontation test: Bedside screening
• Goldmann perimetry: Manual kinetic perimetry (good for peripheral fields)
• Humphrey automated perimetry: Standard for glaucoma monitoring
• Amsler grid: Tests central 10° field; detects macular distortion (metamorphopsia)

Light and Dark Adaptation

• First 5-10 min: cone adaptation (faster, less sensitive)
• After 20-40 min: rod adaptation (slower, increases sensitivity ~25,000-fold)
• This bi-phasic "dark adaptation curve" is a classic exam feature
• Overall sensitivity change: 500,000 to 1 million-fold between full light and dark adaptation

1. Photochemical: Rhodopsin regeneration (main mechanism, slow - minutes to hours)
2. Pupillary changes: ~30-fold, very fast (fraction of a second)
3. Neural adaptation: Only a few-fold, but rapid (seconds)

• Rhodopsin bleaches → rods saturate → cones take over
• Initial visual bleaching (temporary blindness) → adapts within minutes

Visual Reflexes

• Afferent: CN II → pretectal nucleus (midbrain)
• Efferent: Edinger-Westphal nucleus → CN III → ciliary ganglion → sphincter pupillae
• Both direct (same eye) and consensual (opposite eye) responses occur
• Absent in optic nerve lesion (no consensual in affected eye); preserved if lesion is cortical

• Blur on retina → frontal cortex → Edinger-Westphal → ciliary muscle + pupil constriction + medial rectus convergence

Clinical Correlations

Drugs for Visual Acuity Disorders

• See glaucoma table in Chapter 147 for IOP management
• Anti-VEGF for AMD (as above)
• Brinzolamide/Dorzolamide: Topical CAIs for ocular hypertension

---

Chapter 147 - Color Vision

Trichromatic Theory (Young-Helmholtz)

• L-cones (Red): peak ~560 nm (wavelength 647-723 nm)
• M-cones (Green): peak ~530 nm (wavelength 492-575 nm)
• S-cones (Blue): peak ~420 nm (wavelength 450-492 nm)

• Red-Green opponent cells subtract one input from another
• Blue-Yellow opponent cells
• This occurs at ganglion cell level and LGN

Color Vision Processing in Cortex

• P-cells (parvocellular) → LGN layers 3-6 → V1 layer 4 → "Blobs" in V1 layers 2-3 → V4 (color processing area)
• Lesion of V4 → Achromatopsia (cerebral color blindness, color looks grey)
• V8 area: specifically concerned with color vision in humans; lesion → achromatopsia

Color Blindness

• X-linked color blindness skips generations and appears in males of every second generation

• Ishihara plates: Colored spot figures on similar-colored background; screens red-green defects
• Farnsworth-Munsell 100 hue test: Quantitative, detects all types
• Anomaloscope: Gold standard for type/severity

Clinical / Drug Correlations - Color Vision

---

Chapter 148 - Movements of the Eye

Types of Eye Movements

Neural Control of Eye Movements

• CN III (Oculomotor): Superior rectus, inferior rectus, medial rectus, inferior oblique, levator palpebrae
• CN IV (Trochlear): Superior oblique
• CN VI (Abducens): Lateral rectus

• Frontal Eye Field (FEF) → Pontine Paramedian Reticular Formation (PPRF) → ipsilateral CN VI nucleus → lateral rectus (ipsilateral) AND via MLF → contralateral CN III nucleus → medial rectus
• PPRF = horizontal gaze center

• RiMLf (Rostral Interstitial Nucleus of MLF) - vertical gaze center in midbrain
• Also Interstitial Nucleus of Cajal

• Medial Longitudinal Fasciculus (MLF): connects CN VI and CN III nuclei for conjugate horizontal gaze

Clinical Correlations - Eye Movements

Drugs Affecting Eye Movements

---

Master Drug Table for All Eye Disorders

Glaucoma (Most Tested Pharmacology)

• iDose TR implant: Sustained-release travoprost implant; continuous drug delivery for ~3 years
• Durysta: Bimatoprost intracameral implant lasting ~30 months
• SLT (Selective Laser Trabeculoplasty): Now considered first-line in some guidelines; 2024 studies show slight superiority over drops for visual field preservation
• MIGS (Minimally Invasive Glaucoma Surgery): iStent, Hydrus microstent

Wet AMD

Summary of All Treatment Targets

Photoreceptor defects → Vitamin A, gene therapy (Luxturna)
Intraocular pressure ↑ → Prostaglandins, β-blockers, CAIs, cholinomimetics
Wet AMD (new vessels) → Anti-VEGF injections
Dry AMD (geographic atrophy) → Complement inhibitors (C3/C5)
Optic neuritis (MS/NMOSD) → IV Methylprednisolone; biologic immunotherapy
Giant cell arteritis → High-dose steroids (immediate)
Color vision drug toxicity → Withdraw offending drug (ethambutol, chloroquine)
Eye movement disorders → Botulinum toxin (strabismus); memantine/4-AP (nystagmus)
Pupillary disorders → Pilocarpine, atropine, phenylephrine (diagnostic/therapeutic)

---

Quick Clinical Summary - Visual Field Defects at a Glance

Left Eye           Right Eye
 ___                ___
|   |  1. ON → Blind one eye (monocular)
|___|

CHIASM → Bitemporal hemianopia (nasal fibers cross)
  ⊗ ⊗

LEFT OPTIC TRACT → Right homonymous hemianopia
  _ ▓               ▓ _

MEYER'S LOOP (temporal) → Upper right quadrantanopia ("pie in sky")

PARIETAL RADIATION → Lower right quadrantanopia

OCCIPITAL CORTEX → Congruent right homonymous hemianopia + MACULAR SPARING

---